Advertisement
MDCX vs SNY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDCX is a Hold and SNY is a Buy.
MDCX in -3.68% downward trend, sliding for three consecutive days on October 22, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MDCX declined for three days, in 99 of 109 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDCX as a result. In 40 of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for MDCX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 22 similar instances when the indicator turned negative. In 19 of the 22 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The Aroon Indicator for MDCX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDCX advanced for three days, in 69 of 83 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
MDCX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MDCX's P/B Ratio (-106.529) is very low in comparison to the industry average of (-3.019). P/E Ratio (-1.110) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. MDCX's P/S Ratio (0.000) is slightly lower than the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MDCX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
SNY's RSI Oscillator ascending out of oversold territory
The RSI Indicator for SNY moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 19 of the 27 cases the stock moved higher. This puts the odds of a move higher at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 61 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 23 of 48 cases over the following month. The odds of a continued upward trend are 48%.
Following a +2.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 156 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SNY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SNY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.453) is normal, around the industry mean (-3.019). P/E Ratio (25.508) is within average values for comparable stocks, (21.251). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.189) is considerably higher than the industry average of (0.041). P/S Ratio (1.829) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
SNY | ||
|---|---|---|
OUTLOOK RATING 1..100 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 87 | |
SMR RATING 1..100 | 81 | |
PRICE GROWTH RATING 1..100 | 69 | |
P/E GROWTH RATING 1..100 | 8 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MDCX | SNY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 49% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 48% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 47% |
| Advances ODDS (%) | 18 days ago 83% | 7 days ago 51% |
| Declines ODDS (%) | 1 day ago 90% | 10 days ago 52% |
| BollingerBands ODDS (%) | 1 day ago 75% | 1 day ago 57% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 52% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDCX’s FA Score shows that 2 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).
- MDCX’s FA Score: 2 green, 3 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDCX’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).
- MDCX’s TA Score: 4 bullish, 4 bearish.
- SNY’s TA Score: 4 bullish, 4 bearish.
Price Growth
MDCX (@Pharmaceuticals: Major) experienced а -14.10% price change this week, while SNY (@Pharmaceuticals: Major) price change was +3.02% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +5.45%.
Reported Earning Dates
MDCX is expected to report earnings on Nov 13, 2026.
SNY is expected to report earnings on Oct 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.73% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MDCX and
Correlation & Price change
A.I.dvisor tells us that MDCX and BMY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDCX and BMY's prices will move in lockstep.
| Ticker / NAME | Correlation To MDCX | 1D Price Change % | ||
|---|---|---|---|---|
| MDCX | 100% | -2.24% | ||
| BMY - MDCX | 29% Poorly correlated | +3.08% | ||
| SNY - MDCX | 21% Poorly correlated | +2.42% | ||
| MRK - MDCX | 15% Poorly correlated | -1.76% | ||
| NVS - MDCX | 14% Poorly correlated | +1.52% | ||
| AMGN - MDCX | 13% Poorly correlated | +2.04% | ||
More | ||||
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To SNY | 1D Price Change % | ||
|---|---|---|---|---|
| SNY | 100% | +2.42% | ||
| PFE - SNY | 47% Loosely correlated | +1.91% | ||
| JNJ - SNY | 36% Loosely correlated | +3.81% | ||
| MRK - SNY | 35% Loosely correlated | -1.76% | ||
| AMGN - SNY | 35% Loosely correlated | +2.04% | ||
| GILD - SNY | 34% Loosely correlated | +2.36% | ||
More | ||||